Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer
https://doi.org/10.21518/2079-701X-2018-10-140-145
Abstract
Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course.
About the Authors
V. A. Kostorov
State Budget Healthcare Institution «Leningrad regional oncology dispensary»
Russian Federation
Russian Federation
T. Yu. Semiglazova
Federal State Budget Healthcare Institution «National Medical Research Oncology Center named after N.N. Petrov»
Russian Federation
Russian Federation
A. V. Pavlysh
Federal State Budget Healthcare Institution «National Medical Research Oncology Center named after N.N. Petrov»
Russian Federation
Russian Federation
References
1. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer, 2004 Jan 1, 100(1): 44-52.
2. Feinstein AJ. Older Women With Localized Breast Cancer: Costs And Survival Rates Increased Across Two Time Periods. Health Aff, 2015 April, 34(4): 592-600.
3. Dolgin E. Cancer’s cost conundrum. Nature, 2018. S29.
4. Piccart-Gebhart MJ. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med, 2005, 353: 1659-1672.
5. Gianni L et al Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010 Jan 30, 375(9712): 377-84.
6. Untch M et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol, 2010 Apr 20, 28(12): 2024-31.
7. Untch M et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracyclinetaxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol, 2012 Feb, 13(2): 135-44.
8. Prof Luca Gianni et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 2016 June, 17(6): 791-800.
9. Kim M et al. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer M. Ann Oncol, 2013, 24(8): 1999-2004.
10. Schneeweiss A et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology, 2013 September 1, 24(Issue 9): 2278-2284.
11. Attard L et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. Journal of Medical Economics, 2015, 18(3): 173-188.
12. Yagudina RI, Kulikov AYu, Metelkin IA. The cost-effectiveness analysis methodology in pharmacoeconomic studies. Farmakoekonomika, 2012, 5 (4).
13. Yagudina RI, et al. Evaluation of the effectiveness of therapy and methods of pharmacoeconomic research. Farmakoekonomika, 2012, 5 (4).
14. Analysis of the “cost of illness”: types, methodology, features of the analysis in the Russian Federation Yagudina RI, et al. Farmakoekonomika, Volume 5, No 1, 2012
15. Yagudina RI, et al. Features of the pharmacoeconomic research methodology in the context of healthcare of the Russian Federation (review of publications for the period from 1995 to 2007). Farmakoekonomika. 2009, 1: 3-6.
16. Ignatieva VI, Khachatryan GR. Pharmacoeconomic analysis of dual target neoadjuvant therapy in patients with HER2 positive breast cancer. Meditsinskie Tehnologii. Otsenka i Vybor, 2016, 1.
17. Yagudina RI, Kulikov AYu, Nguyen TT, Musina NZ. Pharmacoeconomic analysis of the Russian treatment standard for breast cancer. Farmakoekonomika, 2009, 2 (4).
Review
For citations:
Kostorov VA, Semiglazova TY, Pavlysh AV. Clinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer. Meditsinskiy sovet = Medical Council. 2018;(10):140-145. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-140-145
Views:
845
Email this article 